Abbott Laboratories: A Snapshot of Performance Amid Market Challenges

With a market valuation of $202.6 billion, Abbott Laboratories (ABT), headquartered in North Chicago, Illinois, stands as a significant player in the global healthcare industry. The company specializes in discovering, developing, manufacturing, and selling a diverse array of healthcare products across multiple sectors, including pharmaceuticals, diagnostics, nutrition, and medical devices. Abbott operates in various markets globally, encompassing both emerging and developed regions.

As a “mega-cap” stock, Abbott fits within the elite circle of companies valued over $200 billion. It is particularly noted for its innovative medical devices, such as the FreeStyle Libre continuous glucose monitoring system, which has significantly changed diabetes management.

Nevertheless, Abbott’s stock has dipped nearly 4% from its 52-week high of $121.64. Over the past three months, ABT shares have increased by 3.1%, falling short of the Nasdaq Composite’s ($NASX) 9.5% return during the same period.

On a year-to-date basis, ABT has posted a growth of 6.1%, while the NASX has soared by 29.3%. Over the last 52 weeks, Abbott’s shares have appreciated by 11.4%, which pales in comparison to the NASX’s impressive 35.6% return.

However, since August, ABT has been trading above its 200-day and 50-day moving averages, signaling a bullish trend despite minor fluctuations.

Several factors have contributed to Abbott’s underperformance, including unfavorable currency exchange rates, decreasing demand for COVID-19 testing, and rising costs for raw materials and freight. Additionally, there has been a decline in sales within its Diagnostics segment, though segments like Diabetes Care and Established Pharmaceuticals have experienced growth.

On October 16, the stock gained 1.5% following Abbott’s Q3 earnings report, which exceeded expectations. The company reported revenue of $10.6 billion, a 5% increase from the previous year, with adjusted net income rising by 6% to $2.1 billion. Both of these figures surpassed analysts’ predictions. Moreover, Abbott has raised its full-year 2024 adjusted earnings guidance to between $4.64 and $4.70 per share, estimating revenue growth of 9.5% to 10%.

When comparing performance, ABT has outperformed its competitor Johnson & Johnson (JNJ), which has declined by 2.3% over the past year and by 1.2% year-to-date.

Despite its underwhelming performance relative to the broader market in the previous year, analysts are optimistic about Abbott’s future. The stock boasts a consensus rating of “Strong Buy” from 24 analysts. Currently, ABT is trading below the mean price target of $132.59.

On the date of publication,
Sohini Mondal
did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy
here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.